The earnings call was predominantly positive, with significant growth in global medical cannabis revenue, record adjusted EBITDA, and a strong balance sheet with no debt. Challenges included a decline in consumer cannabis revenue and seasonal fluctuations in plant propagation. Overall, the company's outlook remains optimistic with expectations of continued growth and positive cash flow.

Company Guidance

In the earnings call for Aurora Cannabis Inc. (ACB.TO) for Q2 2025, the company reported strong financial performance and outlined several key metrics. Net revenue grew by 29%, with notable record revenue from global medical cannabis, which saw a 41% year-over-year increase. International medical cannabis revenue also surged by 93%, with international sales composing 57% of total global medical cannabis revenue. Aurora achieved a record adjusted EBITDA of $10.1 million, marking a 210% increase, and its eighth consecutive quarter of positive adjusted EBITDA. The company maintained a consolidated adjusted gross margin of 54%, 300 basis points higher than the previous year. Aurora continues to focus on its high-margin medical cannabis segment, which accounted for 76% of total revenue and 98% of adjusted gross profit. The company ended the quarter with approximately $152 million in cash and cash equivalents, and its cannabis operations remain debt-free. Aurora anticipates continued growth in global medical cannabis, especially in Europe and Australia, and expects to achieve positive free cash flow in Q3.

Global Medical Cannabis Revenue Growth

Net revenue grew 29% including record revenue from global medical cannabis, which represented a 41% year-over-year growth. International revenue increased by 93%.

Record Adjusted EBITDA

Adjusted EBITDA grew 210% to $10.1 million, marking the company's eighth consecutive quarter of positive adjusted EBITDA.

Strong Balance Sheet

The company ended the quarter with approximately $152 million in cash and cash equivalents and no debt in its cannabis business.

Expansion in Australia

Aurora became #2 in Australia, with high regulatory standards providing significant barriers to entry for competitors. The company announced an enhanced product range of premium medical cannabis oils in Australia.

Positive Outlook for Fiscal 2025

Company anticipates positive free cash flow in Q3 and sustained growth in global medical cannabis.

---

Aurora Cannabis (TSE:ACB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:ACB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Sep 24, 2018	2018 (Q4)	- / 2.04	-0.119	1814.29% (+2.16)	―	―
Nov 12, 2018	2019 (Q1)	- / 1.44	0.119	1110.08% (+1.32)	―	―
Feb 11, 2019	2019 (Q2)	- / -3.00	0.237	-1365.82% (-3.24)	―	―
May 14, 2019	2019 (Q3)	- / -1.92	-0.475	-304.21% (-1.44)	―	―
Sep 11, 2019	2019 (Q4)	- / 0.00	2.04	―	―	―
Nov 14, 2019	2020 (Q1)	- / 0.12	1.44	-91.67% (-1.32)	―	―
Feb 13, 2020	2020 (Q2)	- / -14.16	-3	-372.00% (-11.16)	―	―
May 14, 2020	2020 (Q3)	- / -13.70	-19.2	28.65% (+5.50)	―	―
Sep 22, 2020	2020 (Q4)	- / -166.60	0	―	―	―
Nov 09, 2020	2021 (Q1)	- / -9.00	1.2	-850.00% (-10.20)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

TSE:ACB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2024	C$8.46	C$7.11	-15.96%
Aug 07, 2024	C$8.11	C$8.59	+5.92%
Jun 20, 2024	C$7.73	C$7.54	-2.46%
Feb 08, 2024	C$5.20	C$5.40	+3.85%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---